Disclosed is a test device to detect pregnancy In a human female subject, the test device comprising: an assay means to measure the absolute or relative amount of hCG m a sample from the subject; an assay means to measure the absolute or relative amount of FSH in a sample from the subject; and m assay means to measure the absolute or relative amount of one or mere progesterone metabolites I>> a sample from the subject.

The present disclosure relates to devices and methods for identifying conditions in a human or animal body, such as pregnancy or ovulation. For example, the present disclosure relates to devices and methods for identifying pregnancy or ovulation, which devices and methods are adapted to mitigate the hook effect, thereby improving accuracy of the devices and methods.

Disclosed herein are devices, systems, methods and kits for performing immunoassay tests on a sample. The immunoassay devices may be used in conjunction with diagnostic reader systems for obtaining a sensitive read-out of the immunoassay results. The immunoassay devices may be especially suited for the detection of at least a first analyte and a second analyte in a sample. The immunoassay devices and methods may utilize a competitive binding-like assay and a sandwich binding assay to detect analytes in a sample.

The present invention provides polymersomes comprising amphiphilic block-copolymers and their use to quantify ammonia in samples (e.g., body fluid samples). More particularly, it provides a polymersome comprising (a) a membrane, which comprises a block copolymer of poly(styrene) (PS) and poly(ethylene oxide) (PEO), wherein the PS/PEO molecular weight ratio is higher than 1.0 and lower than 4.0; and (b) a core which encloses an acid and at least one pH-sensitive dye. Compositions, strips and kits comprising the polymersomes are also provided along with methods of quantifying ammonia in a sample using the polymersomes, compositions and kit.

The described invention provides a method of functionally reprogramming adult cells to an immature cell type that expresses one or more embryonic biomarkers. The reprogramming is accomplished by contacting the adult cells with a platelet rich fraction comprising platelet-like cells from umbilical cord blood or peripheral blood, and expanding the immature cell type in vitro under culture conditions to generate an insulin-producing cell population that expresses human beta-cell specific transcription factors and is functionally equivalent to human pancreatic beta-cells. Without being limited by theory, platelet-like cells and their released mitochondria display immune tolerance-associated markers that may modulate the function and differentiation of immune cells. The described invention further provides a pharmaceutical composition comprising a cell product containing a therapeutic amount of an insulin-producing cell population derived from functionally reprogrammed adult cells, wherein the insulin-producing cell population expresses human beta-cell specific transcription factors and is functionally equivalent to human pancreatic beta-cells.

Assays used in conjunction with a thermal contrast reader are disclosed. In the assay, the test strip includes materials that can develop a thermal response if a target analyte is present in a sample. Linear flow assays include nanoparticles with high affinity binding to the analyte. Binding of the nanoparticles with an analyte in the sample is detected using thermal contrast. Analytes over a broad range of concentrations are detected in the linear flow assays. Methods of detecting target analytes and kits comprising lateral flow assays and thermal contrast reader are also disclosed.

Described herein are various principles related to collecting and analyzing fertility data for female humans. The underlying concept is that a woman's hormones fluctuate throughout the menstrual cycle, affecting optimal exercise routines and general health practices. A dedicated sensor may be used to collect fertility data, or an estimate may be derived from the individual's menstrual history. Once collected or estimated, the fertility data is factored with other variables to determine the optimal exercise routine or general health habits for the woman. The recommendations are communicated to the woman, who may provide feedback to further improve future recommendations.

There is disclosed a device for pregnancy detection is provided, the device comprising: a central main body comprising a first end and a second end; a pregnancy detection element that is mounted at an edge of the second opening, and an upper longitudinal crease and a lower longitudinal crease, wherein the device is opened by applying simultaneous pressure to the upper longitudinal crease and the lower longitudinal crease, wherein, when in operation, the first opening of the first end is configured to receive urine from a female user while the female user is in a standing position and enables the urine to pass through the pregnancy detection element, and wherein, when the urine comes in contact with the pregnancy detection element, the pregnancy detection element immunologically detects human chorionic gonadotropin (hCG) present in the urine of the female user and indicates positive pregnancy result if the female user is pregnant.

A kit and method for evaluation of the quality and the operating parameters of any types of fully automated open ELISA instruments are disclosed. The kit and method can be used to reliably assess quality control parameters including precision, volume removal accuracy, plate reader accuracy, plate reader linearity, plate washer quality, drift absence, and carryover absence. The evaluation can be completed in a timely and cost-effective manner and provide laboratories with the ability to readily validate the operation and performance of a fully automated ELISA instrument.

A dual indicator light pregnancy testing device is provided. The pregnancy testing device includes a liquid absorbent tip disposed on a first end of a housing wherein the tip includes a channel that permits the flow of urine therethrough. A sensor is provided on an end of the channel adapted to provide a pregnancy reading when contacted with urine that has flowed through the channel disposed on the tip. A first indicator light is disposed on a housing on a second end of the pregnancy testing device and is designed to flash light of a first color when a proper amount of urine is received. A second indicator light is disposed on the housing and is designed to flash a light of a second color when the test is complete. The device is configured to provide an easy to use and accurate pregnancy test.